Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sun Yat-sen Univ. SOS1 compound 11
- Development stage
- Unknown
- Lead developer
- Sun Yat-sen University
- Modality
- Small Molecules
01
Overview
Sun Yat-sen Univ. SOS1 compound 11: sourced facts only. name: "Through structure-based optimization, compound 11 was identified with high SOS1 activation potency (p-ERK EC50 = 1.53 μM)." [PMID:37688996]; target: "Through structure-based optimization, compound 11 was identified with high SOS1 activation potency (p-ERK EC50 = 1.53 μM)." [PMID:37688996]; developer: "Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, 510006 Guangzhou, Guangdong, PR China." [PMID:37688996]; modality: "Herein, we discovered small-molecule SOS1 agonists with novel indazole scaffold." [PMID:37688996]
02
Targets
SOS1 (Son of sevenless homolog 1)
Beyond the preview
Go deeper on Sun Yat-sen Univ. SOS1 compound 11.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sun Yat-sen Univ. SOS1 compound 11.